16 results about "Asthma treatment" patented technology

The invention provides an atomizing bottle for treating bronchial asthma, and belongs to the technical research field of medical instruments. In order to solve the problem that liquid medicine cannot be effectively sprayed out after being pressed once after an existing dosing device is used for many times, a medicine storage bottle pressurizing mechanism and a to-be-sprayed cylinder are additionally arranged between a medicine spraying pressing rod and a medicine storage bottle; during use, the medicine spraying pressing rod pressurizes the medicine storage bottle for multiple times through the medicine storage bottle pressurizing mechanism while spraying quantitative medicine liquid in the to-be-sprayed barrel from the nozzle, so that enough medicine liquid in the medicine storage bottle is extracted into the to-be-sprayed barrel, and therefore, in emergency medicine application, it can be guaranteed that the enough and quantitative medicine liquid is sprayed out after a patient presses the medicine liquid once.

The present invention relates to a biomarker for predicting an asthma treatment response to a biological agent and a use thereof, and specifically to a method for predicting an asthma treatment effect

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

The present application relates to the field of intelligent medical auxiliary decision-making technology, and discloses a ladder treatment scheme recommendation method based on asthma control level and drug response phenotype. The present application aims to solve the problem that the existing scheme cannot identify the deep reason of uncontrolled condition, leading to blind step-up treatment. The present application excludes non-compliance interference by checking the drug execution rate, and improves the authenticity of condition assessment. The present application uses environmental exposure characteristics to adaptively correct the exhaled nitric oxide determination threshold, and eliminates the deviation of smoking on inflammation recognition. The present application combines the logic tree voting of multi-dimensional biological indicators to lock the drug response phenotype. Finally, based on the double index of condition state and phenotype, the present application locates the upgrade or transformation treatment path and generates a recommended scheme. The present application realizes the precise typing and differentiated drug administration of asthma treatment, effectively reduces the drug exposure risk of hormone-insensitive patients while ensuring the clinical efficacy.

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

This disclosure relates to JAK1 pathway inhibitors and their use in the treatment of asthma.

A use of SRT2104 in preparation of a drug for treatment of bronchial asthma is provided, relating to the field of bronchial asthma treatment. The comprehensive analysis of the activation effect of SRT2104 on silent information regulator 1 (SIRT1) in the airway epithelium under asthma conditions and its alleviation effect on asthma airway inflammation is conducted. It is demonstrated that SRT2104 can be activated in the airway epithelium under asthma condition and effectively control asthma airway inflammation. A foundation is laid for the discovery of clinical drug targets and the development of drugs for the treatment of bronchial asthma.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

The invention belongs to the field of biological medicine, and discloses a lipid nanoparticle for delivery of miR-125a-3p by aerosol inhalation and application of the lipid nanoparticle in asthma treatment. The lipid nanoparticle comprises a carrier composed of ionized lipid, auxiliary phospholipid, cholesterol and pegylated lipid, miR-125a-3p or a functional analogue thereof encapsulated in the carrier, and an epidermal growth factor receptor (EGFR) ligand coupled to the surface of the carrier. The particles are administrated in an aerosol inhalation mode, therapeutic miRNA can be efficiently delivered to the lung, and targeting and uptake of the particles in airway epithelial cells are enhanced by means of EGFR ligands. According to the preparation, by delivering miR-125a-3p, a downstream RhoA / ROCK1 signal channel is inhibited, and airway epithelium-mesenchymal transition (EMT) is improved, so that airway inflammation, mucus secretion and remodeling are relieved, and a new strategy is provided for asthma treatment.

The invention discloses application of an NTA10 inhibitor Remodelin in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The core pathological link of the allergic asthma is macrophage M2 polarization imbalance, and NAT10 serving as RNA N4-acetylcytidine modified write enzyme can drive the polarization process. Remodelin is used as an NAT10 specific inhibitor, and can be combined with an NAT10 catalytic structural domain to inhibit the activity of acetyltransferase in a targeted manner, so that an M2 polarization signal channel of macrophages induced by IL-4 / IL-13 is blocked. The invention provides an intraperitoneal injection type medicine taking Remodelin as a core active component, and in-vivo and in-vitro experiments prove that the medicine can remarkably reduce airway inflammatory cell infiltration, down-regulate inflammatory factor release, inhibit high secretion of mucus and airway remodeling, reduce the serum IgE level and effectively improve the pathology phenotype of allergic asthma. According to the invention, the asthma treatment value of the Remodelin-NAT10-macrophage M2 polarization regulation axis is disclosed for the first time, the blank of treating asthma through targeted RNA epigenetic modification is filled, and a brand new treatment scheme is provided for severe asthma.

The present invention provides compounds for use in the treatment of lung diseases (particularly asthma), which bind to the cytokines IL-13 and TSLP. Treatment according to the present invention can reduce exhaled nitric oxide (FeNO) levels by at least 18 ppb compared to placebo. Treatment according to the present invention can also reduce eosinophil count, increase FEV1, and / or reduce airway inflammation.

The present application relates to an NLRP3 inflammasome activation inhibitor comprising trichospirolide A or a pharmaceutically acceptable salt thereof.

The application discloses a soft capsule of Phellodendri fruit oil, a preparation method thereof and pharmaceutical use, and belongs to the technical field of biological medicines. The application extracts the Phellodendri fruit oil from Phellodendri fruit by using a supercritical CO2 extraction technology, refines the Phellodendri fruit oil by combining with molecular distillation, and obtains high-purity active ingredients with a myrcene content of greater than or equal to 8 mg / g; the soft capsule of the Phellodendri fruit oil is prepared by optimizing the proportion of accessories and a gradient drying process. Each soft capsule contains 100-500 mg of the Phellodendri fruit oil, the content particle size D90 is less than or equal to 30 microns, and the myrcene retention rate is greater than or equal to 90% after an accelerated test for three months. Pharmacodynamic studies show that the soft capsule of the Phellodendri fruit oil prepared by the application has a significant cough-relieving and phlegm-removing effect. The preparation process is advanced, the product quality is stable, and the application provides a cough and asthma treatment medicine with simple components and controllable quality for clinical use.